Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Leukemia Research

Volumn 36, Issue 7, 2012, Pages 804-805

  Breccia, Massimo ^a   Efficace, Fabio ^b   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Italian Group for Adult Hematologic Diseases GIMEMA Data Center   (Italy)

Author keywords

Adherence; Chronic myeloid leukemia; Imatinib

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

AGE; BASEL ASSESSMENT OF ADHERENCE SCALE; BEHAVIOR CHANGE; CANCER PROGNOSIS; CANCER RESEARCH; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG BLOOD LEVEL; DRUG URINE LEVEL; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERPERSONAL COMMUNICATION; INTERVIEW; LIFESTYLE MODIFICATION; MORISKY MEDICATION ADHERENCE SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; SELF REPORT; SEX DIFFERENCE; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICATION ADHERENCE; PROTEIN KINASE INHIBITORS;

EID: 84862313008     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.032     Document Type: Editorial

References (18)

1. Partridge A., Avorn J., Wang P.S., Winer E.P. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002, 94:652-661.
2. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
3. Breccia M., Efficace F., Alimena G. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far?. Cancer Lett 2011, 300:115-121.
4. Steiner J.F., Gardner E.M. Assessing medication adherence from pharmacy records. Pharmacoepidemiol Drug Saf 2006, 15:575-577.
5. Vander Stichele R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol 1991, 41:27-35.
6. Choo P.W., Rand C.S., Inui T.S., Lee M.L., Cain E., Cordeiro-Breault M., et al. Validation of patient reports, automated pharmacy records and pill count with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999, 37:846-857.
7. Tsang J., Rudychev I., Pescatore S.L. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients on imatinib. J Clin Oncol 2006, 24:6119.
8. Feng W., Henk H., Thomas S., Baladi J., Hatfield A., Goldberg G.A., et al. Compliance and persistency with imatinib. J Clin Oncol 2006, 24:6038.
9. Darkow T., Henk H.J., Thomas S.K., Feng W., Baladi J.F., Goldberg G.A., et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukemia. Pharmacoeconomics 2007, 49:22-30.
10. Halpern R., Barghout V., Williams D. Compliance with imatinib mesylate associated with lower health resource utilization and costs for patients with CML and GIST. Blood 2007, 110:5159.
11. Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachèe P., Benerman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
12. Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
13. Ibrahim A.R., Eliasson L., Apperley J.F., Milojkovic D., Bua M., Szydlo R., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011, 117:3733-3736.
14. Ganesan P., Sagar T.G., Dubashi B., Rajendranath R., Kannan K., Cyriac S., et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011, 86:471-474.
15. Jönsson S., Olsson B., Söderberg J., Wadenvik H. Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study. Ann Hematol 2011, (November). [Epub ahead of print].
16. Yood M.U., Oliveria S.A., Cziraky M., Hirji I., Hamdan M., Davis C. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012, 28:213-219.
17. Gater A., Heron L., Abetz L., Coombs J., Simmons J., Guilhot F., et al. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res 2012, [Epub ahead of print].
18. Efficace F., Baccarani M., Breccia M., Alimena G., Rosti G., Cottone F., et al. Investigating personal and treatment related factors associated with adherence behavior in patients with chronic myeloid leukemia receiving long term imatinib therapy. Blood 2011, 118. abs 1026.